From Mechanism to Disease: Translational Epilepsy Biology

Epilepsy and seizure disorders affect nearly 3 million people in the United States, including civilians and veterans, highlighting the need for improved therapies. The Reddy Lab focuses on developing novel, mechanism-based treatments for epilepsy and related brain disorders, addressing conditions such as catamenial and pediatric epilepsy, status epilepticus, post-traumatic epilepsy (PTE), and chemical and organophosphate neurotoxicity. Through a multidisciplinary approach that combines pharmacology, electrophysiology, histology, mass spectrometry, and transgenic models, the lab has built leading expertise in neurosteroids as innovative anticonvulsants. Their pioneering work has helped establish neurosteroids as key endogenous modulators of neuronal excitability and promising targets for new therapeutic strategies.

Selected Publications

Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis
D.S. Reddy, H.K. Thompson, G. Calderara. Neuroscience Letters Vol. 750 (2021) [PDF] [DOI]

Clinical Pharmacology and Therapeutics of Antiepileptic Drugs for Treatment of Epilepsy and Seizure Disorders
D.S. Reddy. International Journal of Pharmaceutical Sciences and Nanotechnology Vol. 13 Issue 6 (Nov-Dec 2020); doi: 10.37285/ijpsn.2020.13.6.1 pp. 5165-5180 [PDF] [DOI]

Prospects of Modeling Poststroke Epileptogenesis
Doodipala Samba Reddy,* Aamir Bhimani, Ramkumar Kuruba,Min Jung Park, and Farida Sohrabji. Journal of Neuroscience Research Vol. 95 pp. 1000–1016 (2017) [PDF] [DOI]

Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration
Victoria M. Golub, Jonathan Brewer, Xin Wu, Ramkumar Kuruba, Jenessa Short, Maunica Manchi, Megan Swonke, Iyan Younus, D.S. Reddy. Frontiers in Aging Neuroscience Vol. 7 p. 196 (2015); doi: 10.3389/fnagi.2015.00196 [PDF] [DOI]